173 related articles for article (PubMed ID: 22454488)
41. Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy.
Baden LR; Katz JT; Fishman JA; Koziol C; DelVecchio A; Doran M; Rubin RH
Transplantation; 2003 Dec; 76(11):1632-7. PubMed ID: 14702539
[TBL] [Abstract][Full Text] [Related]
42. Long-term visual safety of voriconazole in adult patients with paracoccidioidomycosis.
Laties AM; Fraunfelder FT; Tomaszewski K; Goodrich J; Moreira AT; Sato MT; de Queiroz-Telles F
Clin Ther; 2010 Dec; 32(13):2207-17. PubMed ID: 21316537
[TBL] [Abstract][Full Text] [Related]
43. Phototoxic dermatoses in pediatric BMT patients receiving voriconazole.
Goyal RK; Gehris RP; Howrie D; Cogley KM; Windreich RM; Venkataramanan R
Pediatr Blood Cancer; 2014 Jul; 61(7):1325-8. PubMed ID: 24619922
[TBL] [Abstract][Full Text] [Related]
44. Hope for patients with neoplastic disease and invasive fungal infections.
McLeroth P; Polsky B
J Support Oncol; 2005; 3(4):299-300. PubMed ID: 16092601
[No Abstract] [Full Text] [Related]
45. How does a patient maximally benefit from anti-infective chemotherapy?
Drusano GL
Clin Infect Dis; 2004 Oct; 39(8):1245-6. PubMed ID: 15486851
[No Abstract] [Full Text] [Related]
46. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210
[TBL] [Abstract][Full Text] [Related]
47. Lack of cross-hepatotoxicity between voriconazole and posaconazole.
Foo H; Gottlieb T
Clin Infect Dis; 2007 Sep; 45(6):803-5. PubMed ID: 17712772
[No Abstract] [Full Text] [Related]
48. Voriconazole-induced photosensitivity: photobiological assessment of a case series of 12 patients.
Haylett AK; Felton S; Denning DW; Rhodes LE
Br J Dermatol; 2013 Jan; 168(1):179-85. PubMed ID: 22860570
[TBL] [Abstract][Full Text] [Related]
49. [Role of voriconazole in critically ill patients with invasive mycoses].
Alvarez Lerma F
Rev Iberoam Micol; 2007 Sep; 24(3):209-12. PubMed ID: 17874857
[TBL] [Abstract][Full Text] [Related]
50. Successful voriconazole therapy of disseminated Fusarium verticillioides infection in an immunocompromised patient receiving chemotherapy.
Sagnelli C; Fumagalli L; Prigitano A; Baccari P; Magnani P; Lazzarin A
J Antimicrob Chemother; 2006 Apr; 57(4):796-8. PubMed ID: 16469850
[No Abstract] [Full Text] [Related]
51. [Efficacy of voriconazole for treatment of invasive fungal infections in 87 cases with hematologic malignancies].
Feng AM; Wei JY; Yu WJ
Zhonghua Xue Ye Xue Za Zhi; 2011 Jul; 32(7):473-5. PubMed ID: 22213868
[No Abstract] [Full Text] [Related]
52. Duration of voriconazole exposure: an independent risk factor for skin cancer after lung transplantation.
Zwald FO; Spratt M; Lemos BD; Veledar E; Lawrence C; Marshall Lyon G; Chen SC
Dermatol Surg; 2012 Aug; 38(8):1369-74. PubMed ID: 22551390
[TBL] [Abstract][Full Text] [Related]
53. Voriconazole in an infant with cryptococcal meningitis.
Shen YZ; Wang JR; Lu HZ
Chin Med J (Engl); 2008 Feb; 121(3):286-8. PubMed ID: 18298929
[No Abstract] [Full Text] [Related]
54. Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation.
Martin T; Sharma M; Damon L; Kaplan L; Guglielmo BJ; Working M; O'Malley R; Hwang J; Linker C
Transpl Infect Dis; 2010 Feb; 12(1):45-50. PubMed ID: 19793068
[TBL] [Abstract][Full Text] [Related]
55. Severe acute hypokalaemia secondary to voriconazole. Uncommon pharmacological causes of hypokalaemia.
González Rozas M; Alvarez Tundidor S; Pineda Alonso M
Nefrologia; 2011; 31(1):112-3. PubMed ID: 21270925
[No Abstract] [Full Text] [Related]
56. Fatal dysrhythmia following initiation of lansoprazole during a long-term course of voriconazole.
Tsubokura M; Miura Y; Itokawa T; Murata K; Takei N; Higaki T; Murashige N; Kami M; Komatsu T
J Clin Pharmacol; 2011 Oct; 51(10):1488-90. PubMed ID: 21098688
[No Abstract] [Full Text] [Related]
57. Voriconazole: a new triazole antifungal agent.
Johnson LB; Kauffman CA
Clin Infect Dis; 2003 Mar; 36(5):630-7. PubMed ID: 12594645
[TBL] [Abstract][Full Text] [Related]
58. Voriconazole concentrations and outcome of invasive fungal infections.
Miyakis S; van Hal SJ; Ray J; Marriott D
Clin Microbiol Infect; 2010 Jul; 16(7):927-33. PubMed ID: 19845698
[TBL] [Abstract][Full Text] [Related]
59. Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices?
Pongas GN; Lewis RE; Samonis G; Kontoyiannis DP
Clin Microbiol Infect; 2009 Oct; 15 Suppl 5():93-7. PubMed ID: 19754766
[TBL] [Abstract][Full Text] [Related]
60. Review: voriconazole for prevention or treatment of invasive fungal infections in cancer with neutropenia.
Morris AM
Ann Intern Med; 2014 Jul; 161(2):JC8. PubMed ID: 25023274
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
